Saturday links: a personal focus
Tadas Viskanta
Abnormal Returns
3 months ago
4 MIN READ
Autos
- Waymo is expanding its geographic reach in 2025. (theverge.com)
- How some new EV buyers feel about their cars. (insidehook.com)
- Many Tesla ($TSLA) vehicles would need a hardware upgrade for FSD. (autoweek.com)
Energy
- Boosting drilling in the U.S. won’t be easy. (grist.org)
- Why are California’s electricity prices higher than the majority of the US? (klementoninvesting.substack.com)
- Waterwheels are still a viable technology. (theguardian.com)
Environment
- Convincing people to leave their homes even after multiple disasters isn’t easy. (ft.com)
- Is it possible to reduce the carbon impact of soccer? (wsj.com)
- Is climate change going to increase territorial disputes? (ft.com)
Travel
- Airlines have become overly dependent on the profits from their loyalty programs. (ft.com)
- For cities, restricting tourists is a balancing act. (nytimes.com)
ATC
- Airport near-misses have been rising. (theatlantic.com)
- Congestion in the Washington DC air space is nothing new. (politico.com)
- More than 90% of the country’s 313 air traffic control facilities are understaffed. (nytimes.com)
- The air safety regime in the U.S. has worked. Now its getting politicized. (theatlantic.com)
Behavior
- Some evidence that creatine be used to help treat depression. (newatlas.com)
- The personal vulnerability you see online, is largely performative. (theatlantic.com)
- Five insights from Ellen Hendriksen’s “How to Be Enough: Self-Acceptance for Self-Critics and Perfectionists.” (nextbigideaclub.com)
Clinical trials
- Challenge trials are on the rise. (nytimes.com)
- You can’t just pause a clinical trial for no good reason. (theconversation.com)
Pharmaceuticals
- The FDA has approved a non-addictive pain killer, Journavx by Vertex Pharmaceuticals ($VRTX). (nytimes.com)
- Ozempic was approved to treat kidney disease for patients with Type 2 diabetes. (cnbc.com)
Health
- We won’t know the danger of missed vaccinations until its too late. (theatlantic.com)
- On the prospects for a urine-based prostate cancer test. (newatlas.com)
- How much of your cancer risk is baked in before birth? (sciencedaily.com)
- How the mom’s microbiome affects a baby’s health. (the-scientist.com)
Fitness
- RICE is out. Minor injury treatment recommendations have changed. (wsj.com)
- A ‘normal’ BMI is not the be all, end all. (gq.com)
- Keep it simple, people. (primecuts.philpearlman.com)
Drugs
- There’s no easy way to interdict fentanyl. (theconversation.com)
- How cannabis use affects brain function. (newatlas.com)
Food
Drink
- Can an app help you drink less? (insidehook.com)
- Some strategies to help reduce your drinking. (wsj.com)
- Do NA drinks help or hurt when it comes to quitting alcohol? (fastcompany.com)
- Choosing to drink is a risk-return question. (wsj.com)
- Alcohol use and retirees. (marketwatch.com)
Music
- Bands that were not appreciated in their time including ‘The Smiths.’ (statsignificant.com)
- On the death of the B-side. (whyisthisinteresting.substack.com)
Sports betting
- Consumers in states without legal sports betting can use Kalshi to bet on the Super Bowl. (axios.com)
- There is a limit to what you can bet on in prediction markets. (wsj.com)
- Young men are the target market for sports betting. (theguardian.com)
- Is ‘responsible gambling’ an oxymoron? (sportico.com)
Youth
- You can’t really produce too many STEM majors. (agglomerations.substack.com)
- Young American adults are having less sex. (ifstudies.org)
Earlier on Abnormal Returns
- What you missed in our Friday linkfest. (abnormalreturns.com)
- Podcast links: our AI future. (abnormalreturns.com)
- Why ‘critical ignoring’ is a crucial skill these days. (abnormalreturns.com)
- You can now follow us on Bluesky. (bsky.app)
- Have you signed up for daily e-mail newsletter? Well, you should. (abnormalreturns.com)
Mixed media
Terms and Conditions
This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.
The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.
References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.
Please see disclosures here.
